Repare Therapeutics (NASDAQ:RPTX) Announces Earnings Results

Repare Therapeutics (NASDAQ:RPTX) released its quarterly earnings data on Monday. The company reported ($0.67) EPS for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.10, Zacks reports. Repare Therapeutics had a negative return on equity of 40.87% and a negative net margin of 99.76%.

Repare Therapeutics Price Performance

Shares of NASDAQ:RPTX opened at $1.16 on Tuesday. The stock has a market cap of $49.31 million, a P/E ratio of -0.58 and a beta of 0.88. Repare Therapeutics has a 1-year low of $1.06 and a 1-year high of $7.28. The firm has a fifty day moving average price of $1.26 and a 200 day moving average price of $2.47.

Analysts Set New Price Targets

RPTX has been the topic of a number of research analyst reports. Lifesci Capital reissued a “market perform” rating on shares of Repare Therapeutics in a report on Friday, December 13th. Stifel Nicolaus cut their price target on shares of Repare Therapeutics from $9.00 to $4.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Repare Therapeutics in a research note on Friday, November 8th. Finally, Bloom Burton cut Repare Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 10th.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.